A Phase I Study With an Expansion Cohort of the PARP [poly (ADP-ribose)-polymerase-1] inhibitor AZD2281 (olaparib, KU-0059436) Combined With Carboplatin in Breast and Ovarian Cancer in BRCA1/2 Mutation Carriers and Familial Breast and Ovarian Cancer.

Trial Profile

A Phase I Study With an Expansion Cohort of the PARP [poly (ADP-ribose)-polymerase-1] inhibitor AZD2281 (olaparib, KU-0059436) Combined With Carboplatin in Breast and Ovarian Cancer in BRCA1/2 Mutation Carriers and Familial Breast and Ovarian Cancer.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Apr 2014

At a glance

  • Drugs Olaparib (Primary) ; Carboplatin
  • Indications Advanced breast cancer; Ovarian cancer
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 09 Apr 2014 Results for the triple-negative breast cancer cohort presented at the 105th Annual Meeting of the American Association for Cancer Research.
    • 14 Oct 2009 Planned number of patients changed from 45 to 101 as reported by ClinicalTrials.gov.
    • 18 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top